福元医药：关于子公司获得药品补充申请批准通知书的公告

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary, Fuyuan Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the "Salicylic Acid Phenol Plaster," transferring the marketing authorization from Xi'an Kanghua Pharmaceutical Co., Ltd. to Fuyuan Pharmaceutical Co., Ltd. [1] Group 1 - Fuyuan Pharmaceutical announced the approval of a new drug, indicating a significant development in its product portfolio [1] - The drug's marketing authorization has been transferred, which may enhance Fuyuan Pharmaceutical's market position and operational control [1]